Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

2.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K
Cytoskeletal Linker Proteins - Plakins01:09

Cytoskeletal Linker Proteins - Plakins

3.0K
Plakins are large proteins with binding domains for microtubules, microfilaments, intermediate filaments, and membrane-associated protein complexes at cell junctions. Plakin functions are evolutionarily conserved and are primarily involved in organizing the different components of the cytoskeleton by crosslinking them to each other and connecting them to the cell-matrix and cell adhesion complexes. They are also known to interact with signal transducers, serve as scaffolds for signaling...
3.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

9.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.9K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.4K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.4K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

14.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
14.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term endocrine and testicular outcomes in male survivors of childhood acute lymphoblastic leukemia.

Journal of endocrinological investigation·2026
Same author

A Multicenter Retrospective Study Comparing Immunosuppressive Therapy Combined with Eltrombopag to Immunosuppressive Therapy Alone as Frontline Treatment for Pediatric Severe Aplastic Anemia

Turkish journal of haematology : official journal of Turkish Society of Haematology·2025
Same author

Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study.

Research and practice in thrombosis and haemostasis·2024
Same author

Alu-Mediated Deletion of FANCA in Turkish Families With Fanconi Anemia: Evidence of a Founder Effect.

American journal of medical genetics. Part A·2024
Same author

Experience with Pediatric Chronic Immune Thrombocytopenia over 30 Years in the Era before Eltrombopag.

Children (Basel, Switzerland)·2024
Same author

Prognosis of Second Primary Malignancies in Pediatric Acute Lymphoblastic Leukemia Survivors: A Multicenter Study by the Turkish Pediatric Hematology Society.

Journal of pediatric hematology/oncology·2024

Related Experiment Video

Updated: Mar 15, 2026

Author Spotlight: Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus
06:45

Author Spotlight: Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus

Published on: June 2, 2023

2.9K

Plasminogen deficiency.

Tiraje Celkan1

  • 1Departments of Pediatric Hematology-Oncology, Cerrahpasa Faculty of Medicine, İstanbul University, Armakent B2/8 Konaklar Mah. Şebboy Sok. 4.Levent-İstanbul, 80620, Istanbul, Turkey. tirajecelkan@yahoo.com.

Journal of Thrombosis and Thrombolysis
|September 16, 2016
PubMed
Summary

Congenital plasminogen deficiency causes ligneous conjunctivitis, a rare disorder. Topical plasminogen eye drops show promise for treating this condition, offering a potential new therapy.

Keywords:
HydrocephalusLigneous conjunctivitisLigneous gingivitisPlasminogen deficiency

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K
Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

12.1K

Related Experiment Videos

Last Updated: Mar 15, 2026

Author Spotlight: Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus
06:45

Author Spotlight: Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus

Published on: June 2, 2023

2.9K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K
Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

12.1K

Area of Science:

  • Ophthalmology
  • Genetics
  • Biochemistry

Background:

  • Plasminogen is crucial for fibrinolysis, wound healing, cell migration, tissue remodeling, and angiogenesis.
  • Congenital plasminogen deficiency is a rare autosomal recessive disorder.
  • This deficiency can lead to the formation of thick, woody pseudomembranes on mucosal surfaces, primarily affecting the conjunctiva, a condition known as ligneous conjunctivitis.

Purpose of the Study:

  • To investigate the role of plasminogen in ocular health.
  • To explore treatment options for ligneous conjunctivitis.
  • To highlight the potential of topical plasminogen therapy.

Main Methods:

  • Review of existing literature on plasminogen function and deficiency.
  • Analysis of clinical presentation and management of ligneous conjunctivitis.
  • Evaluation of therapeutic strategies, including fresh frozen plasma (FFP) and potential plasminogen eye drops.

Main Results:

  • Congenital plasminogen deficiency is the underlying cause of ligneous conjunctivitis.
  • Current management often involves local conjunctival application of fresh frozen plasma (FFP) alongside other medications like cyclosporine and artificial tears.
  • Topical plasminogen eye drops represent a promising, yet currently unavailable, therapeutic approach.

Conclusions:

  • Plasminogen deficiency significantly impacts ocular health, leading to ligneous conjunctivitis.
  • While FFP offers symptomatic relief, topical plasminogen eye drops present a more targeted and potentially effective treatment.
  • Further development and availability of plasminogen eye drops are needed, particularly in regions like Turkey.